Cargando…

A plasma miRNA-based classifier for small cell lung cancer diagnosis

INTRODUCTION: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveil...

Descripción completa

Detalles Bibliográficos
Autores principales: Saviana, Michela, Romano, Giulia, McElroy, Joseph, Nigita, Giovanni, Distefano, Rosario, Toft, Robin, Calore, Federica, Le, Patricia, Morales, Daniel Del Valle, Atmajoana, Sarah, Deppen, Stephen, Wang, Kai, Lee, L. James, Acunzo, Mario, Nana-Sinkam, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585112/
https://www.ncbi.nlm.nih.gov/pubmed/37869089
http://dx.doi.org/10.3389/fonc.2023.1255527
Descripción
Sumario:INTRODUCTION: Small cell lung cancer (SCLC) is characterized by poor prognosis and challenging diagnosis. Screening in high-risk smokers results in a reduction in lung cancer mortality, however, screening efforts are primarily focused on non-small cell lung cancer (NSCLC). SCLC diagnosis and surveillance remain significant challenges. The aberrant expression of circulating microRNAs (miRNAs/miRs) is reported in many tumors and can provide insights into the pathogenesis of tumor development and progression. Here, we conducted a comprehensive assessment of circulating miRNAs in SCLC with a goal of developing a miRNA-based classifier to assist in SCLC diagnoses. METHODS: We profiled deregulated circulating cell-free miRNAs in the plasma of SCLC patients. We tested selected miRNAs on a training cohort and created a classifier by integrating miRNA expression and patients’ clinical data. Finally, we applied the classifier on a validation dataset. RESULTS: We determined that miR-375-3p can discriminate between SCLC and NSCLC patients, and between SCLC and Squamous Cell Carcinoma patients. Moreover, we found that a model comprising miR-375-3p, miR-320b, and miR-144-3p can be integrated with race and age to distinguish metastatic SCLC from a control group. DISCUSSION: This study proposes a miRNA-based biomarker classifier for SCLC that considers clinical demographics with specific cut offs to inform SCLC diagnosis.